Natalizumab treatment of multiple sclerosis: new insights

Serena Delbue, Manola Comar, Pasquale Ferrante

Research output: Contribution to journalReview article

Abstract

Natalizumab is a monoclonal antibody directed against the α4 chain of the very late activating antigen 4 and α4β7 integrins, present on the leukocytes surface, used as monotherapy for the treatment of relapsing-remitting multiple sclerosis. It substantially reduces relapse rate and the accumulation of disability, but its use is associated with a very adverse event, that is the development of progressive multifocal leukoencephalopathy, a fatal demyelinating disease of the CNS, due to the lytic replication of the human polyomavirus JC. The main focus of the review is to describe the newest insights on natalizumab, its current use in the clinical practice, the natalizumab-treated patients' management and the risk stratification related to the progressive multifocal leukoencephalopathy development.

Original languageEnglish
Pages (from-to)157-171
Number of pages15
JournalImmunotherapy
Volume9
Issue number2
DOIs
Publication statusPublished - Jan 1 2017

Fingerprint

Multiple Sclerosis
Progressive Multifocal Leukoencephalopathy
JC Virus
Integrin alpha4beta1
Relapsing-Remitting Multiple Sclerosis
Risk Management
Demyelinating Diseases
Integrins
Leukocytes
Therapeutics
Monoclonal Antibodies
Recurrence
Natalizumab

Keywords

  • disease modifying therapy
  • multiple sclerosis
  • natalizumab
  • progressive multifocal leukoencephalopathy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Oncology

Cite this

Natalizumab treatment of multiple sclerosis : new insights. / Delbue, Serena; Comar, Manola; Ferrante, Pasquale.

In: Immunotherapy, Vol. 9, No. 2, 01.01.2017, p. 157-171.

Research output: Contribution to journalReview article

Delbue, Serena ; Comar, Manola ; Ferrante, Pasquale. / Natalizumab treatment of multiple sclerosis : new insights. In: Immunotherapy. 2017 ; Vol. 9, No. 2. pp. 157-171.
@article{fe8dc9327698408dae646dd89ab0c7de,
title = "Natalizumab treatment of multiple sclerosis: new insights",
abstract = "Natalizumab is a monoclonal antibody directed against the α4 chain of the very late activating antigen 4 and α4β7 integrins, present on the leukocytes surface, used as monotherapy for the treatment of relapsing-remitting multiple sclerosis. It substantially reduces relapse rate and the accumulation of disability, but its use is associated with a very adverse event, that is the development of progressive multifocal leukoencephalopathy, a fatal demyelinating disease of the CNS, due to the lytic replication of the human polyomavirus JC. The main focus of the review is to describe the newest insights on natalizumab, its current use in the clinical practice, the natalizumab-treated patients' management and the risk stratification related to the progressive multifocal leukoencephalopathy development.",
keywords = "disease modifying therapy, multiple sclerosis, natalizumab, progressive multifocal leukoencephalopathy",
author = "Serena Delbue and Manola Comar and Pasquale Ferrante",
year = "2017",
month = "1",
day = "1",
doi = "10.2217/imt-2016-0113",
language = "English",
volume = "9",
pages = "157--171",
journal = "Immunotherapy",
issn = "1750-743X",
publisher = "Future Medicine Ltd.",
number = "2",

}

TY - JOUR

T1 - Natalizumab treatment of multiple sclerosis

T2 - new insights

AU - Delbue, Serena

AU - Comar, Manola

AU - Ferrante, Pasquale

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Natalizumab is a monoclonal antibody directed against the α4 chain of the very late activating antigen 4 and α4β7 integrins, present on the leukocytes surface, used as monotherapy for the treatment of relapsing-remitting multiple sclerosis. It substantially reduces relapse rate and the accumulation of disability, but its use is associated with a very adverse event, that is the development of progressive multifocal leukoencephalopathy, a fatal demyelinating disease of the CNS, due to the lytic replication of the human polyomavirus JC. The main focus of the review is to describe the newest insights on natalizumab, its current use in the clinical practice, the natalizumab-treated patients' management and the risk stratification related to the progressive multifocal leukoencephalopathy development.

AB - Natalizumab is a monoclonal antibody directed against the α4 chain of the very late activating antigen 4 and α4β7 integrins, present on the leukocytes surface, used as monotherapy for the treatment of relapsing-remitting multiple sclerosis. It substantially reduces relapse rate and the accumulation of disability, but its use is associated with a very adverse event, that is the development of progressive multifocal leukoencephalopathy, a fatal demyelinating disease of the CNS, due to the lytic replication of the human polyomavirus JC. The main focus of the review is to describe the newest insights on natalizumab, its current use in the clinical practice, the natalizumab-treated patients' management and the risk stratification related to the progressive multifocal leukoencephalopathy development.

KW - disease modifying therapy

KW - multiple sclerosis

KW - natalizumab

KW - progressive multifocal leukoencephalopathy

UR - http://www.scopus.com/inward/record.url?scp=85011062087&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011062087&partnerID=8YFLogxK

U2 - 10.2217/imt-2016-0113

DO - 10.2217/imt-2016-0113

M3 - Review article

AN - SCOPUS:85011062087

VL - 9

SP - 157

EP - 171

JO - Immunotherapy

JF - Immunotherapy

SN - 1750-743X

IS - 2

ER -